Before developing any stakeholder engagement plan, it is crucial to have a clear understanding of all the relevant individuals and groups your product or device could directly impact or interest in
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh